Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity evidence from a large population of French centenarians

Atherosclerosis

Volumn 136, Issue 2, 1998, Pages 389-394

  Thillet, J ^a   Doucet, C ^a   Chapman, J ^a   Herbeth, B ^b   Cohen, D ^c   Faure Delanef, L ^c  

^a 'Lipoproteines et A   (France)

^b Centre de Medecine Preventive   (France)

^c FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

Apo(a) isoform; Centenarians; Lipoprotein(a)

Indexed keywords

CHOLESTEROL; LIPOPROTEIN A; TRIACYLGLYCEROL;

ADULT; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FRANCE; HUMAN; LONGEVITY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS A; CHOLESTEROL; FEMALE; FRANCE; HUMANS; LIPOPROTEIN(A); LONGEVITY; MALE; TRIGLYCERIDES;

EID: 0032006960     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00217-7     Document Type: Article

References (31)

1. Schächter F., Faure-Delanef L., Guénot F., Rouger H., Froguel P., Lesueur-Ginot L., Cohen D. Genetic association with human longevity at the APOE and ACE loci. Nat. Genet. 6:1994;29-32.
2. Takata H., Ishii T., Suzuki M., Sekiguchi S., Iri H. Influence of major histocompatibility complex region genes in human longevity among Okinawan-Japanese centenarians and nonagenarians. Lancet. 11:1987;824-826.
3. Dammerman M., Breslow J.L. Genetic basis of lipoprotein disorders. Circulation. 91:1995;505-512.
4. McLean J.W., Tomlinson J.E., Kuang W.J., Eaton D.L., Chen E.Y., Fless G.M., Scanu A.M., Lawn R.M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330:1987;132-137.
5. Lackner C., Boerwinkle E., Leffert C.C., Rahmig T., Hobbs H.H. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulse-field electrophoresis. J Clin Invest. 87:1991;2153-2161.
6. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 80:1987;458-465.
7. Cambillau M., Simon A., Amar J., Giral P., Atger V., Segond P., Levenson J., Merli I., Megnien J.L., Plaifosse M.C., Moatti N., Group P. Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. Arterioscler Thromb. 12:1992;1346-1352.
8. Pepin J.M., O'Neil J.A., Hoff H.F. Quantification of apo(a) and apo B in human atherosclerotic lesions. J Lipid Res. 32:1991;317-327.
9. Smith E.B., Keen G.A., Grant A. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoproteins. I. Relation between fibrin and immobilization of apo B-containing lipoprotein. Atherosclerosis. 84:1990;165-171.
10. Miles L.A., Fless G.M., Levin E.G., Scanu A.M., Plow E.F. A potential basis for the thrombotic risks associated with apolipoprotein(a). Nature. 339:1989;301-303.
11. Loscalzo J., Weinfield M., Fless G.M., Scanu A.M. Lipoprotein(a), fibrin binding and plasminogen activation. Arterioscler Thromb. 10:1990;240-245.
12. Grainger D.J., Kirschenlohr H.L., Metcalfe J.C., Weissberg P.L., Wade D.P., Lawn R.M. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 260:1993;1655-1658.
13. Faure-Delanef L, Quéré I, Chassé JF, Guerassimenko O, Lesaulnier M, Bellet H, Zittoun J, Kamoun P, Cohen D. MTHFR thermolabile variant and human longevity. Am J Hum Genet 1997, in press.
14. Doucet C., Huby T., Chapman J., Thillet J. Lipoprotein[a] in the chimpanzee - relationship of apo[a] phenotype to elevated plasma Lp[a] levels. J Lipid Res. 35:1994;263-270.
15. Guo H.C., Armstrong V.W., Luc G., Billardon C., Goulinet S., Nustede R., Seidel D., Chapman J.M. Characterization of five mouse monoclonal antibodies to apolipoprotein(a) from human Lp(a): evidence for weak plasminogen reactivity. J Lipid Res. 30:1989;23-37.
16. Kamboh M.I., Ferrell R.E., Kottke B.A. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet. 49:1991;1063-1074.
17. Sandholzer C., Saha N., Kark J.D., Rees A., Jaross W., Dieplinger H., Hoppichler F., Boerwinkle E., Utermann G. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb. 12:1992;1214-1226.
18. Jenner J.L., Ordovas J.M., Lamonfava S., Schaefer M.M., Wilson P.W.F., Castelli W.P., Schaefer E.J. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels - The Framingham Offspring Study. Circulation. 87:1993;1135-1141.
19. Wood W.G., Schumacher M. Lipoprotein(a) concentrations in non-selected hospitalised patients between 18 and 100 years of age: comparison with cholesterol fractions and triacylglycerols in patients with lipid status requests. Eur J Clin Chem Clin Biochem. 33:1995;903-914.
20. Berg K., Ro O.C. Lp(a) lipoprotein level and longevity. Ann Genet. 34:1991;264-269.
21. Knapp R.G., Schreiner P.J., Sutherland S.E., Keil J.E., Gilbert G.E., Klein R.L., Hames C., Tyroler H.A. Serum lipoprotein(a) levels in elderly Black and White men in the Charleston Heart Study. Clin Genet. 44:1993;225-231.
22. Simons L., Friedlander Y., Simons J., McCallum J. Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo study. Atherosclerosis. 99:1993;87-95.
23. Zuliani G., Bader G., Imbastaro T., Mezzetti A., Taddeo U., Kostner G.M., Fellin R. Lipoprotein(a) plasma levels and apo(a) isoforms are not associated with longevity or disability in a sample of Italian octo-nonagenarians. Aging - Clin Exp Res. 7:1995;385-391.
24. Capurso A, Colacicco AM, Resta F, Vespertino E, Fulgido ML, D'Amelio MC, Venezia A. Lp(a) is high in healthy centenarians. 3rd Int Symp Multiple Risk Factors in Cardiovascular Disease, 1994 (Abstract).
25. Malaguarnera M., Ruello P., Rizzo M., Receputo G., Rapisarda R., Restuccia N., Pistone G. Lipoprotein(a) levels in centenarians. Arch Gerontol Geriatr. 5:1996;385-388.
26. Cigolini M., Seidell J.C., Zenti M.G., Bonadonna G., Zambelli L., Deslypere J.P., Contaldo F., Cruz A., Charzewska J., Targher G., Muggeo M. Serum Lp(a) levels in randomized healthy men from different European countries. Eur J Epidemiol. 9:1993;497-503.
27. Parra H.J., Evans A.E., Cambou J.P., Amouyel P., Bingham A., McMaster D., Schaffer P., Douste-Blazy P., Luc G., Richard J.L., Ducimetiere P., Fruchart J.C., Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM study. Arterioscler Thromb. 12:1992;701-707.
28. Mancini F.P., Mooser V., Guerra R., Hobbs H.H. Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum Mol Genet. 4:1995;1535-1542.
29. Boonmark N.W., Schwartz K., Lou X., Pearle A.D., Rubin E.M., Lawn R.M. The role of apo(a) lysine binding site in atherosclerosis. Circulation. 94:1996;I-38.
30. Hervio L., Chapman M.J., Thillet J., Loyau S., Anglescano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis. Blood. 82:1993;392-397.
31. Leerink C.B., Duif P.F.C.C.M., Gimpel J.A., Kortlandt W., Bouma B.N., van Rijn H.J.M. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation. Thromb Haemost. 68:1992;185-188.